News Headline Summary

MannKind (MNKD) wins FDA approval for Afrezza for treatment of diabetes; FDA has boxed warning on Afrezza on acute bronchospasm

Reaction details (20:35)

- In an immediate reaction MNKD shares rose 3.8% from USD 10.70 to USD 11.11 before the announcement that the FDA approved drug can cause bronchospasm which resulted in the shares falling 14.4% to USD 9.51 before being halted. 

27 Jun 2014 - 20:25 - Equities - Source: BBG

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: